Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
CapEx to Revenue
5.14%
Quarterly · Period ending:
LCTX CapEx to Revenue
Latest reported5.14%period ending
Latest reported5.14%period ending
LCTX Quarterly CapEx/Revenue (0.00% → 5.14%)
Latest values, visible window
High-resolution chart · PNG
LCTX capex to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | CapEx to Revenue |
|---|---|
| 12.147% | |
| 4.5175% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 164.584% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |